An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Mosunetuzumab (Primary) ; Polatuzumab vedotin (Primary) ; Bendamustine; Rituximab; Tocilizumab
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 29 Oct 2019 Planned number of patients changed from 282 to 262.
- 06 Mar 2019 Planned number of patients changed from 276 to 282.
- 06 Feb 2019 Planned End Date changed from 28 Sep 2023 to 18 Jun 2022.